In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
Amikacin, combined with aztreonam, piperacillin, or ticarcillin, synergistically inhibited amikacin-resistant sputum isolates of Pseudomonas aeruginosa and P. cepacia from children with cystic fibrosis. Ticarcillin-amikacin was the least active combination. Aminoglycoside resistance should not preclude the use of beta-lactam-aminoglycoside combinations in the treatment of pulmonary infections in cystic fibrosis.
D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004359:Drug Therapy, Combination; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D010403:Penicillin Resistance; D010878:Piperacillin / Q000494:pharmacology; D011552:Pseudomonas Infections / Q000150:complications / Q000382:microbiology*; D013982:Ticarcillin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D007612:Kanamycin; D000583:Amikacin; D013982:Ticarcillin; D001398:Aztreonam; D010878:Piperacillin